289 related articles for article (PubMed ID: 22529163)
1. Baseline characteristics of subjects enrolled in the Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) trial.
Chertow GM; Correa-Rotter R; Block GA; Drueke TB; Floege J; Goodman WG; Herzog CA; Kubo Y; London GM; Mahaffey KW; Mix TC; Moe SM; Wheeler DC; Parfrey PS
Nephrol Dial Transplant; 2012 Jul; 27(7):2872-9. PubMed ID: 22529163
[TBL] [Abstract][Full Text] [Related]
2. Cinacalcet HCl: a novel treatment for secondary hyperparathyroidism caused by chronic kidney disease.
Torres PU
J Ren Nutr; 2006 Jul; 16(3):253-8. PubMed ID: 16825031
[TBL] [Abstract][Full Text] [Related]
3. The clinical course of treated hyperparathyroidism among patients receiving hemodialysis and the effect of cinacalcet: the EVOLVE trial.
Parfrey PS; Chertow GM; Block GA; Correa-Rotter R; Drüeke TB; Floege J; Herzog CA; London GM; Mahaffey KW; Moe SM; Wheeler DC; Dehmel B; Trotman ML; Modafferi DM; Goodman WG
J Clin Endocrinol Metab; 2013 Dec; 98(12):4834-44. PubMed ID: 24108314
[TBL] [Abstract][Full Text] [Related]
4. Effects of cinacalcet on atherosclerotic and nonatherosclerotic cardiovascular events in patients receiving hemodialysis: the EValuation Of Cinacalcet HCl Therapy to Lower CardioVascular Events (EVOLVE) trial.
Wheeler DC; London GM; Parfrey PS; Block GA; Correa-Rotter R; Dehmel B; Drüeke TB; Floege J; Kubo Y; Mahaffey KW; Goodman WG; Moe SM; Trotman ML; Abdalla S; Chertow GM; Herzog CA;
J Am Heart Assoc; 2014 Nov; 3(6):e001363. PubMed ID: 25404192
[TBL] [Abstract][Full Text] [Related]
5. Cinacalcet and achievement of the NKF/K-DOQI recommended target values for bone and mineral metabolism in real-world clinical practice--the ECHO observational study.
Ureña P; Jacobson SH; Zitt E; Vervloet M; Malberti F; Ashman N; Leavey S; Rix M; Os I; Saha H; Ryba M; Bencova V; Baños A; Zani V; Fouque D
Nephrol Dial Transplant; 2009 Sep; 24(9):2852-9. PubMed ID: 19369690
[TBL] [Abstract][Full Text] [Related]
6. The ADVANCE study: a randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis.
Raggi P; Chertow GM; Torres PU; Csiky B; Naso A; Nossuli K; Moustafa M; Goodman WG; Lopez N; Downey G; Dehmel B; Floege J;
Nephrol Dial Transplant; 2011 Apr; 26(4):1327-39. PubMed ID: 21148030
[TBL] [Abstract][Full Text] [Related]
7. Effect of Cinacalcet and Vitamin D Analogs on Fibroblast Growth Factor-23 during the Treatment of Secondary Hyperparathyroidism.
Sprague SM; Wetmore JB; Gurevich K; Da Roza G; Buerkert J; Reiner M; Goodman W; Cooper K
Clin J Am Soc Nephrol; 2015 Jun; 10(6):1021-30. PubMed ID: 25873267
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of Cinacalcet Therapy to Lower Cardiovascular Events (EVOLVE): rationale and design overview.
Chertow GM; Pupim LB; Block GA; Correa-Rotter R; Drueke TB; Floege J; Goodman WG; London GM; Mahaffey KW; Moe SM; Wheeler DC; Albizem M; Olson K; Klassen P; Parfrey P
Clin J Am Soc Nephrol; 2007 Sep; 2(5):898-905. PubMed ID: 17702710
[TBL] [Abstract][Full Text] [Related]
9. A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of cinacalcet HCl in participants with CKD not receiving dialysis.
Chonchol M; Locatelli F; Abboud HE; Charytan C; de Francisco AL; Jolly S; Kaplan M; Roger SD; Sarkar S; Albizem MB; Mix TC; Kubo Y; Block GA
Am J Kidney Dis; 2009 Feb; 53(2):197-207. PubMed ID: 19110359
[TBL] [Abstract][Full Text] [Related]
10. The Effects of Cinacalcet in Older and Younger Patients on Hemodialysis: The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial.
Parfrey PS; Drüeke TB; Block GA; Correa-Rotter R; Floege J; Herzog CA; London GM; Mahaffey KW; Moe SM; Wheeler DC; Kubo Y; Dehmel B; Goodman WG; Chertow GM;
Clin J Am Soc Nephrol; 2015 May; 10(5):791-9. PubMed ID: 25710802
[TBL] [Abstract][Full Text] [Related]
11. Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis.
; Chertow GM; Block GA; Correa-Rotter R; Drüeke TB; Floege J; Goodman WG; Herzog CA; Kubo Y; London GM; Mahaffey KW; Mix TC; Moe SM; Trotman ML; Wheeler DC; Parfrey PS
N Engl J Med; 2012 Dec; 367(26):2482-94. PubMed ID: 23121374
[TBL] [Abstract][Full Text] [Related]
12. Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study.
Lindberg JS; Culleton B; Wong G; Borah MF; Clark RV; Shapiro WB; Roger SD; Husserl FE; Klassen PS; Guo MD; Albizem MB; Coburn JW
J Am Soc Nephrol; 2005 Mar; 16(3):800-7. PubMed ID: 15689407
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic strategies for secondary hyperparathyroidism in dialysis patients.
Ogata H; Koiwa F; Ito H; Kinugasa E
Ther Apher Dial; 2006 Aug; 10(4):355-63. PubMed ID: 16911189
[TBL] [Abstract][Full Text] [Related]
14. Cinacalcet, Fibroblast Growth Factor-23, and Cardiovascular Disease in Hemodialysis: The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial.
Moe SM; Chertow GM; Parfrey PS; Kubo Y; Block GA; Correa-Rotter R; Drüeke TB; Herzog CA; London GM; Mahaffey KW; Wheeler DC; Stolina M; Dehmel B; Goodman WG; Floege J;
Circulation; 2015 Jul; 132(1):27-39. PubMed ID: 26059012
[TBL] [Abstract][Full Text] [Related]
15. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis.
Block GA; Martin KJ; de Francisco AL; Turner SA; Avram MM; Suranyi MG; Hercz G; Cunningham J; Abu-Alfa AK; Messa P; Coyne DW; Locatelli F; Cohen RM; Evenepoel P; Moe SM; Fournier A; Braun J; McCary LC; Zani VJ; Olson KA; Drüeke TB; Goodman WG
N Engl J Med; 2004 Apr; 350(15):1516-25. PubMed ID: 15071126
[TBL] [Abstract][Full Text] [Related]
16. Economic analysis of cinacalcet in combination with low-dose vitamin D versus flexible-dose vitamin D in treating secondary hyperparathyroidism in hemodialysis patients.
Shireman TI; Almehmi A; Wetmore JB; Lu J; Pregenzer M; Quarles LD
Am J Kidney Dis; 2010 Dec; 56(6):1108-16. PubMed ID: 20951487
[TBL] [Abstract][Full Text] [Related]
17. A Randomized Trial of Cinacalcet versus Vitamin D Analogs as Monotherapy in Secondary Hyperparathyroidism (PARADIGM).
Wetmore JB; Gurevich K; Sprague S; Da Roza G; Buerkert J; Reiner M; Goodman W; Cooper K
Clin J Am Soc Nephrol; 2015 Jun; 10(6):1031-40. PubMed ID: 25904755
[TBL] [Abstract][Full Text] [Related]
18. Comparative cost analysis of management of secondary hyperparathyroidism with paricalcitol or cinacalcet with low-dose vitamin D in hemodialysis patients.
Sharma A; Ketteler M; Marshall TS; Khan SS; Schumock GT
J Med Econ; 2013 Sep; 16(9):1129-36. PubMed ID: 23834479
[TBL] [Abstract][Full Text] [Related]
19. Clinical experience with cinacalcet HCl.
Ureña Torres P
Nephrol Dial Transplant; 2004 Aug; 19 Suppl 5():V27-33. PubMed ID: 15284357
[TBL] [Abstract][Full Text] [Related]
20. Combined therapy with cinacalcet and low doses of vitamin D sterols in patients with moderate to severe secondary hyperparathyroidism.
Block GA; Zeig S; Sugihara J; Chertow GM; Chi EM; Turner SA; Bushinsky DA;
Nephrol Dial Transplant; 2008 Jul; 23(7):2311-8. PubMed ID: 18310602
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
